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§

Abstract: We consider inference in randomized studies, in which repeatedly measured outcomes may be informatively missing due to drop out. In this setting, it is well known that
full data estimands are not identified unless unverified assumptions are imposed. We assume a non-future dependence model for the drop-out mechanism and posit an exponential
tilt model that links non-identifiable and identifiable distributions. This model is indexed
by non-identified parameters, which are assumed to have an informative prior distribution,
elicited from subject-matter experts. Under this model, full data estimands are shown to
be expressed as functionals of the distribution of the observed data. To avoid the curse of
dimensionality, we model the distribution of the observed data using a Bayesian shrinkage
model. In a simulation study, we compare our approach to a fully parametric and a fully
saturated model for the distribution of the observed data. Our methodology is motivated
and applied to data from the Breast Cancer Prevention Trial.
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1

Introduction

1.1

Breast Cancer Prevention Trial

The Breast Cancer Prevention Trial (BCPT) was a large multi-center, double-blinded, placebocontrolled, chemoprevention trial of the National Surgical Adjuvant Breast and Bowel Project
(NSABP) designed to test the efficacy of 20mg/day tamoxifen in preventing breast cancer
and coronary heart disease in healthy women at risk for breast cancer (Fisher et al., 1998).
The study was open to accrual from June 1, 1992 through September 30, 1997 and 13,338
women aged 35 or older were enrolled in the study during this interval. The primary objective was to determine whether long-term tamoxifen therapy is effective in preventing the
occurrence of invasive breast cancer. Secondary objectives included quality of life (QOL)
assessments to evaluate benefit as well as risk resulting from the use of tamoxifen.
Monitoring QOL was of particular importance for this trial since the participants were
healthy women and there had been concerns voiced by researchers about the association
between clinical depression and tamoxifen use. Accordingly, data on depression symptoms
was scheduled to be collected at baseline prior to randomization, at 3 months, at 6 months
and every 6 months thereafter for up to 5 years. The primary instrument used to monitor
depressive symptoms over time was the Center for Epidemiologic Studies Depression Scale
(CES-D)(Radloff, 1977). This self-test questionnaire is composed of 20 items, each of which
is scored on a scale of 0-3. A score of 16 or higher is considered as a likely case of clinical
depression.
The trial was unblinded on March 31, 1998, after an interim analysis showed a dramatic
reduction in the incidence of breast cancer in the treatment arm. Due to the potential loss of
the control arm, we focus on QOL data collected on the 10,982 participants who were enrolled
during the first two years of accrual and had their CES-D score recorded at baseline. All
women in this cohort had the potential for three years of follow-up (before the unblinding).
http://biostats.bepress.com/jhubiostat/paper188
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In the BCPT, the clinical centers were not required to collect QOL data on women after
they stopped their assigned therapy. This design feature aggravated the problem of missing
QOL data in the trial. As reported in Land et al. (2002), more than 30% of the CES-D scores
were missing at the 36-month follow-up, with a slightly higher percentage in the tamoxifen
group. They also showed that women with higher baseline CES-D scores had higher rates
of missing data at each follow-up visit and the mean observed CES-D scores preceding a
missing measurement were higher than those preceding an observed measurement; there was
no evidence that these relationships differed by treatment group.
While these results suggest that the missing data process is associated with observed QOL
outcomes, one cannot rule out the possibility that the process is further related to unobserved
outcomes and that this relationship is modified by treatment. In particular, investigators
were concerned (a priori) that, between assessments, tamoxifen might be causing depression
in some individuals, who then do not return for their next assessment. If this occurs, the
data are said be missing not at random (MNAR); otherwise the data are said to be missing
at random (MAR).

1.2

Informative Drop-out in Longitudinal Studies

In this paper, we will concern ourselves with inference in longitudinal studies, where individuals who miss visits do not return for subsequent visits (i.e., drop-out). In such a setting,
MNAR is often referred to as informative drop-out. While there were some intermittent
responses in the BCPT, we will, as in Land et al. (2002), consider a “monotonized” dataset,
whereby all CES-D scores observed on an individual after their first missing score have been
deleted (this increases the “dropout” rate).
There are two main inferential paradigms for analyzing longitudinal studies with informative drop-out: likelihood (parametric) and non-likelihood (semi-parametric). Articles by
Little (1995), Hogan and Laird (1997a) and Kenward and Molenberghs (1999) as well as
recent books by Molenberghs and Kenward (2007) and Daniels and Hogan (2008) provide
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a comprehensive review of likelihood-based approaches, including selection models, patternmixture models, and shared-parameter models. These models differ in the way the joint
distribution of the outcome and missing data processes are factorized. In selection models,
one specifies a model for the marginal distribution of the outcome process and a model for
the conditional distribution of the drop-out process given the outcome process (see, for example, Heckman, 1979; Diggle and Kenward, 1994; Baker, 1995; Fitzmaurice et al., 1995;
Molenberghs et al., 1997; Liu et al., 1999; Albert, 2000); in pattern-mixture models, one
specifies a model for the conditional distribution of the outcome process given the drop-out
time and the marginal distribution of the drop-out time (see, for example, Little, 1993, 1994,
1995; Hogan and Laird, 1997b; Fitzmaurice and Laird, 2000; Daniels and Hogan, 2000; Roy,
2003; Birmingham and Fitzmaurice, 2002; Thijs et al., 2002; Pauler et al., 2003; Roy and
Daniels, 2008); and in shared-parameter models, the outcome and drop-out processes are
assumed to be conditionally independent given shared random effects (see, for example, Wu
and Carroll, 1988; DeGruttola and Tu, 1994; Ten Have et al., 1998, 2000; Pulkstenis et al.,
1998; Land et al., 2002; Yuan and Little, 2009). Traditionally, these models have relied on
very strong distributional assumptions in order to obtain model identifiability.
Without these strong distributional assumptions, specific parameters from these models
would not be identified from the distribution of the observed data. To address this issue
within a likelihood-based framework, several authors (Nordheim, 1984; Baker et al., 1992;
Little, 1994; Little and Rubin, 1999; Kurland and Heagerty, 2004; Daniels and Hogan, 2008)
have promoted the use of global sensitivity analysis, whereby non- or weakly- identified, interpretable parameters are fixed and then varied to evaluate the robustness of the inferences.
Scientific experts can be employed to constrain the range of these parameters.
Non-likelihood approaches to informative drop-out in longitudinal studies have been primarily developed from a selection modeling perspective. Here, the marginal distribution of
the outcome process is modeled non- or semi-parametrically and the conditional distribution
of the drop-out process given the outcome process is modeled semi- or fully- parametrically.
http://biostats.bepress.com/jhubiostat/paper188
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In the case where the drop-out process is assumed to depend only on observable outcomes
(i.e., MAR), Robins et al. (1994, 1995), van der Laan and Robins (2003) and Tsiatis (2006)
developed inverse-weighted and augmented inverse-weighted estimating equations for inference. For informative drop-out, Rotnitzky et al. (1998), Scharfstein et al. (1999) and
Rotnitzky et al. (2001) introduced a class of selection models, in which the model for dropout is indexed by interpretable sensitivity parameters that express departures from MAR.
Inference using inverse-weighted estimating equations was proposed.
The problem with the aforementioned sensitivity analysis approaches is that the ultimate
inferences can be cumbersome to display. Vansteelandt et al. (2006) developed a method for
reporting ignorance and uncertainty intervals (regions) that contain the true parameter(s) of
interest with a prescribed level of precision, when the true data generating model is assumed
to fall within a plausible class of models (as an example, see Scharfstein et al., 2004). An
alternative and very natural strategy is specify an informative prior distribution on the nonor weakly- identified parameters and conduct a fully Bayesian analysis, whereby the ultimate
inferences are reported in terms of posterior distributions. In the cross-sectional setting with
a continuous outcome, Scharfstein et al. (2003) adopted this approach from a semi-parametric
selection modeling perspective. Kaciroti et al. (2009) proposed a parametric pattern-mixture
model for cross-sectional, clustered binary outcomes . Lee et al. (2008) introduced a fullyparametric pattern-mixture approach in the longitudinal setting with binary outcomes. In
this paper, we consider the same setting as Lee et al. (2008), but offer a more flexible strategy.
In the context of BCPT, the longitudinal outcome will be the indicator that the CES-D score
is 16 or higher.

1.3

Outline

The paper is organized as follows. In Section 2, we describe the data structure. In Section
3 and 4, we formalize identification assumptions and prove that the full-data distribution
is identified under these assumptions. We introduce a saturated model for the distribution
Hosted by The Berkeley Electronic Press
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of the observed data in Section 5. In Section 6, we illustrate how to apply shrinkage priors
to high-order interaction parameters in the saturated model to reduce the dimensionality
of the parameter space and how to elicit (conditional) informative priors for non-identified
sensitivity parameters from experts. In Section 7, we assess, by simulation, the behavior
of three classes of models for the distribution of observed data; parametric, saturated, and
shrinkage. Our analysis of the BCPT trial is presented in Section 8. Section 9 is devoted to
a summary and discussion.

2

Data Structure and Notation

Let Z denote the treatment assignment indicator, where Z = 1 denotes tamoxifen and
Z = 0 denotes placebo. Let Yj denote the binary outcome (i.e., depression) scheduled to
be measured at the jth visit (j = 0(baseline), . . . , J) and let Y j = (Y0 , . . . , Yj ) denote
the history of the outcome process through visit j. Let Rj denote the indicator that an
individual has her depression status recorded at visit j. We assume that R0 = 1 (i.e., Y0
is always observed) and Rj = 0 implies that Rj+1 = 0 (i.e., monotone missing data). Let
C = max{t : Rt = 1} be the last visit at which an individual’s depression status is recorded.
The full and observed data for an individual are F = (Z, C, Y J ) and O = (Z, C, Y C ),
respectively. We assume that we observe n i.i.d., copies of O. We will use the subscript i to
denote data for the ith individual.
Our goal is to draw inference about µ∗z,j = P [Yj = 1|Z = z] for j = 1, . . . , J and z = 0, 1.

3

Assumptions

To identify µ∗z,j from the distribution of the observed data, we make the following two
untestable assumptions:
Assumption 1 (Non-Future Dependence): Rj is independent of (Yj+1 , . . . , YJ ) given
Rj−1 = 1 and Y j , for j = 1, . . . , J − 1.
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This assumption asserts that for individuals at risk for drop-out at visit j and who share
the same history of outcomes up to and including visit j, the distribution of future outcomes
is the same for those who are last seen at visit j and those who remain on study past visit
j. This assumption has been referred to as non-future dependence (Kenward et al., 2003).
Assumption 2 (Pattern-Mixture Representation): For j = 1, . . . , J and yj = 0, 1,
P [Yj = yj |Rj = 0, Rj−1 = 1, Y j−1 , Z = z] =
P [Yj = yj |Rj = 1, Y j−1 , Z = z] exp{qz,j (Y j−1, yj )}
E[exp{qz,j (Y j−1 , Yj )}|Rj = 1, Y j−1 , Z = z]
where qz,j (Y j−1 , Yj ) is a specified function of its arguments.
Assumption 2 links the non-identified conditional distribution of Yj given Rj = 0, Rj−1 =
1, Y j−1, and Z = z to the identified conditional distribution of Yj given Rj = 1, Y j−1 , and
Z = z using exponential tilting via the specified function qz,j (Y j−1, Yj ). Assumption (2) has
a selection model representation that is obtained using Bayes’ rule.
Assumption 2 (Selection Model Representation): For j = 1, . . . , J,
logit {P [Rj = 0|Rj−1 = 1, Y j , Z = z]} = hz,j (Y j−1) + qz,j (Y j−1 , Yj )
where
hz,j (Y j−1 ) = logit P [Rj = 0|Rj−1 = 1, Y j−1 , Z = z] −
log{E[exp{qz,j (Y j−1 , Yj )}|Rj−1 = 1, Y j−1 , Z = z]}
With this characterization, we see that the function qz,j (Y j−1, Yj ) quantifies the influence
(on a log odds ratio scale) of the potentially unobservable outcome Yj on the conditional
odds of dropping at time j.

4

Identifiability

The above two assumptions non-parametrically, just-identify µ∗z,j for all j = 1, . . . , J and
z = 0, 1. To see this, consider the following representation of this conditional distribution,
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derived using the laws of total and conditional probability:
X

µ∗z,j =

P [Yj = 1|Rj = 1, Y j−1 = y j−1, Z = z]×

y j−1
( j
Y

P [Rl = 1|Rl−1 = 1, Y l−1 = y l−1 , Z = z]

XX
k=1

)

P [Yl = yl |Rl = 1, Y l−1 = y l−1 , Z = z] +

l=0

l=1

j

j−1
Y

P [Yj = 1|Rk = 0, Rk−1 = 1, Y k−1 = y k−1 , Z = z]P [Rk = 0|Rk−1 = 1, Y k−1 = y k−1 , Z = z]

y k−1
(k−1
)
k−1
Y
Y
P [Yl = yl |Rl = 1, Y l−1 = y l−1 , Z = z]
P [Rl = 1|Rl−1 = 1, Y l−1 = y l−1 , Z = z]
×
l=0

l=1

All quantities on the right hand side of this equation are identified, without appealing to any
assumptions, except P [Yj = 1|Rk = 0, Rk−1 = 1, Y k−1 = y k−1 , Z = z] for k = 1, . . . , j − 1.
Under Assumptions 1 and 2, these probabilities can be shown to be identified, implying that
µ∗z,j is identified for all j and z.
Theorem 1: P [Yj = 1|Rk−1 = 1, Y k−1 = y k−1 , Z = z] and P [Yj = 1|Rk = 0, Rk−1 =
1, Y k−1 = y k−1 , Z = z] are identified for k = 1, . . . , j.
Proof: The proof follows by backward induction. Consider k = j. By Assumption 2,
P [Yj = 1|Rj = 0, Rj−1 = 1, Y j−1 = y j−1, Z = z] =
P [Yj = 1|Rj = 1, Y j−1 , Z = z] exp{qz,j (Y j−1, 1)}
E[exp{qz,j (Y j−1 , Yj )}|Rj = 1, Y j−1 = y j−1, Z = z]
Since the right hand side is identified, we know that P [Yj = 1|Rj = 0, Rj−1 = 1, Y j−1 =
y j−1 , Z = z] is identified. Further, we can write
P [Yj = 1|Rj−1 = 1, Y j−1 = y j−1 , Z = z]
=

1
X

P [Yj = 1|Rj = r, Rj−1 = 1, Y j−1 = y j−1, Z = z]P [Rj = r|Rj−1 = 1, Y j−1 = y j−1, Z = z]

r=0

Since all quantities on the right hand side are identified, P [Yj = 1|Rj−1 = 1, Y j−1 =
y j−1 , Z = z] is identified.
http://biostats.bepress.com/jhubiostat/paper188
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Suppose that P [Yj = 1|Rk = 0, Rk−1 = 1, Y k−1 = y k−1 , Z = z] and P [Yj = 1|Rk−1 =
1, Y k−1 = y k−1 , Z = z] are identified for some k where 1 < k < j. Then, we need to show
that these probabilities are identified for k ′ = k − 1. To see this, note that
P [Yj = 1|Rk′ = 0, Rk′ −1 = 1, Y k′ −1 = y k′ −1 , Z = z]
= P [Yj = 1|Rk−1 = 0, Rk−2 = 1, Y k−2 = y k−2 , Z = z]
=

1
X

P [Yj = 1|Rk−1 = 0, Rk−2 = 1, Y k−1 = y k−1 , Z = z]×

1
X

P [Yj = 1|Rk−1 = 1, Y k−1 = y k−1 , Z = z]×

yk−1 =0

P [Yk−1 = yk−1|Rk−1 = 0, Rk−2 = 1, Y k−2 = y k−2, Z = z]

=

yk−1 =0

P [Yk−1 = yk−1|Rk−1 = 1, Y k−2 = y k−2 , Z = z] exp{qz,k−1(Y k−2 , yk−1)}
E[exp{qz,k−1(Y k−2 , Yk−1)}|Rk−1 = 1, Y k−2 = y k−2 , Z = z]

The third equality follows by Assumptions 1 and 2. Since all the quantities on the right hand
side of the last equality are identified, P [Yj = 1|Rk′ = 0, Rk′ −1 = 1, Y k′ −1 = y k′ −1 , Z = z] is
identified. Further,
P [Yj = 1|Rk′−1 = 1, Y k′ −1 = y k′ −1 , Z = z]
= P [Yj = 1|Rk−2 = 1, Y k−2 = y k−2 , Z = z]
=

1
X

P [Yj = 1|Rk−1 = 1, Y k−1 = y k−1, Z = z]×

yk−1 =0

P [Yk−1 = yk−1|Rk−1 = 1, Y k−2 = y k−2 , Z = z]×
P [Rk−1 = 1|Rk−2 = 1, Y k−2 = y k−2 , Z = z]+

1
X

P [Yj = 1|Rk−1 = 0, Rk−2 = 1, Y k−1 = y k−1 , Z = z]×

yk−1 =0

P [Yk−1 = yk−1|Rk−1 = 0, Y k−2 = y k−2 , Z = z]×
P [Rk−1 = 0|Rk−2 = 1, Y k−2 = y k−2 , Z = z]

=

1
X

P [Yj = 1|Rk−1 = 1, Y k−1 = y k−1, Z = z]×

yk−1 =0

P [Yk−1 = yk−1|Rk−1 = 1, Y k−2 = y k−2 , Z = z]×
P [Rk−1 = 1|Rk−2 = 1, Y k−2 = y k−2 , Z = z]+
9
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1
X

P [Yj = 1|Rk−1 = 1, Y k−1 = y k−1, Z = z]×

yk−1 =0

P [Yk−1 = yk−1|Rk−1 = 1, Y k−2 = y k−2 , Z = z] exp{qz,k−1(Y k−2 , yk−1)}
×
E[exp{qz,k−1(Y k−2 , Yk−1)}|Rk−1 = 1, Y k−2 = y k−2, Z = z]
P [Rk−1 = 0|Rk−2 = 1, Y k−2 = y k−2 , Z = z]

The third equality follows by Assumptions 1 and 2. Since all the quantities on the right
hand side of the last equality are identified, P [Yj = 1|Rk′ −1 = 1, Y k′ −1 = y k′−1 , Z = z] is
identified.



The identifiability result shows that, given the functions qz,j (Y j−1, Yj ), µ∗z,j can be expressed as functional of the distribution of the observed data. In particular, the functional
depends on the conditional distributions of Yj given Rj = 1, Y j−1 , and Z for j = 0, . . . , J and
the conditional distributions of Rj given Rj−1 = 1, Y j−1 and Z for j = 1, . . . , J. Furthermore, the functions qz,j (Y j−1 , Yj ) are not identifiable from the distribution of the observed
data and their specification places no restrictions on the distribution of the observed data.

5

Modeling

We specify saturated models for the observed data via the sequential conditional distributions
of [Yj |Rj = 1, Y j−1 , Z] for j = 0, . . . , J and the conditional hazards [Rj |Rj−1 = 1, Y j−1, Z]
for j = 1, . . . , J. We parameterize these models as follows:
logit P [Y0 = 1|R0 = 1, Z = z] = αz,0,0
logit P [Yj = 1|Rj = 1, Y j−1 = y j−1, Z = z] = αz,j,0 + αz,j,1yj−1 +

j−2
X

(1)

αz,j,k yk

k=0

+

X

(2)
αz,j,·yk yl

+

(2)
k,l∈Aj

X

(3)
αz,j,·yk yl ym

+ ...+

(j−1)
αz,j y0 y1

· ·yj−1

(3)
k,l,m∈Aj

logit P [Rj = 0|Rj−1 = 1, Y j−1 = y j−1 , Z = z] = γz,j,0 + γz,j,1yj−1 +

j−2
X

(1)

γz,j,k yk

k=0

+

X

(2)
k,l∈Aj

(2)
γz,j,·yk yl

+

X

(3)
γz,j,·yk yl ym

+ ...+

(j−1)
γz,j y0 y1

· ·yj−1

(3)
k,l,m∈Aj
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(t)

for j = 1, . . . , J, where Aj is the set of all t-tuples of the integers 0, . . . , j − 1. Let α denote
the parameters indexing the conditional distributions [Yj |Rj = 1, Y j−1 , Z], γ denote the
parameters indexing the conditional distributions [Rj |Rj−1 = 1, Y j−1 , Z] and θ = {α, γ}.
Furthermore, we propose to parameterize the functions qz,j (Y j−1 , Yj ) with parameters
τz,j,yj−1 = qz,j ((y j−1 , 1)) − qz,j ((y j−1 , 0)). Here, exp(τz,j,yj−1 ) represents, in the context of
the BCPT trial, the conditional odds ratio of dropping out between visits j − 1 and j for
individuals who are depressed vs. not depressed at visit j, but share the mental history y j−1
through visit j − 1. We let τ denote the collection of τz,j,yj−1 ’s.

6

Prior Specification and Posterior Computation

For specified sensitivity analysis parameters τ , the saturated model proposed in Section 5
provides a perfect fit to the distribution of the observed data. In this model, however, the
number of parameters increases exponentially in J. In contrast, the number of data points
increases linearly in J. As a consequence, there will be many combinations of y j−1 (i.e.,
”cells”) which will be sparsely represented in the dataset. For example, in the BCPT trial,
about 50% of the possible realizations of Y 7 have less than two observations and about 15%
have no observations. For a frequentist perspective, this implies that components of θ will
be imprecisely estimated; in turn, this can adversely affect estimation of µ∗z,j . This has been
called the curse of dimensionality (Robins and Ritov, 1997).

6.1

Shrinkage Priors on θ

To address this problem, we introduce data driven shrinkage priors for higher order interactions to reduce the number of parameters in an automated manner. In particular, we
assume
(t)

αz,j,k ∼ N(0, σα(t) )

and

(t)

γz,j,k ∼ N(0, σγ(t) )

(t)

k ∈ Aj , 3 ≤ t < j ≤ J, z = 0, 1

(1)
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where t is the order of interactions and the hyper-parameters (shrinkage variances) follow
distributions
σα(t) ∼ Unif(0, 10)
(t)

and

σγ(t) ∼ Unif(0, 10).

(t)

When σα and σγ equal zero for all interactions, the saturated model is reduced to a first
order Markov model,
logit P [Y0 = 1|R0 = 1, Z = z] = αz,0,0
logit P [Yj = 1|Rj = 1, Y j−1 = y j−1 , Z = z] = αz,j,0 + αz,j,1yj−1
logit P [Rj = 0|Rj−1 = 1, Y j−1 = y j−1 , Z = z] = γz,j,0 + γz,j,1yj−1.
The shrinkage priors allow the “neighboring” cells in the observed data model to borrow
information from each other and provide more precise estimates.
When the first order Markov model is not true, as n goes to infinity, the posterior means
of observed data probabilities will converge to their true values as long as the shrinkage priors
are O(1) (which is the case here) and all the true values of the observed data probabilities,
P [Yj |Rj = 1, Y j−1 , Z] for j = 0, . . . , J and are in the open interval, (0, 1). This follows,
since under this latter condition, all combinations of depression histories have a positive
probability of being observed and the prior will become swamped by the observed data.
However, when the true value of any of the observed data probabilities is zero or one, there
exists at least one combination of depression history that will never be observed and thus
the influence of the prior will not dissipate as n increases.
We specify non-informative priors N(0, 1000) for the non-interaction parameters in θ,
namely αz,j,0 for j = 0, . . . , J and z = 0, 1, αz,j,1, γz,j,0 and γz,j,1 for j = 1, . . . , J and
z = 0, 1.

http://biostats.bepress.com/jhubiostat/paper188
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6.2

τ given θ

The sensitivity parameters in Assumption 2, defined formally in Section 5, are (conditional)
odds ratios. In our experience, subject matter experts often have difficulty thinking in terms
of odds ratios; rather, they are more comfortable expressing beliefs about relative risks
(Scharfstein et al., 2006; Shepherd et al., 2007). With this is in mind, we asked Dr. Patricia
Ganz, a medical oncologist and expert on quality of life outcomes in breast cancer, to express
her beliefs about the risk of dropping out and its relationship to treatment assignment and
depression. We then translated her beliefs into prior distributional assumptions about the
odds ratio sensitivity parameters τ .
Specifically, we asked Dr. Ganz to answer the following question for each treatment
group:
Q: Consider a group of women assigned to placebo (tamoxifen), who are on study through
visit j − 1 and who share the same history of depression. Suppose that the probability that a
randomly selected woman in this group drops out before visit j is p (denoted by the columns
in Table 1). For each p, what is the minimum, maximum and your best guess (median)
representing how much more (e.g. twice) or less (e.g., half ) likely you consider the risk of
dropping out before visit j for a woman who would be depressed at year j RELATIVE to a
woman who would not be depressed at visit j?
Implicit in this question is the assumption that, for each treatment group, the relative
risk only depends on past history and the visit number only through the risk of dropping
out between visits j − 1 and j.
For notational convenience, let rz (p) denote the relative risk of drop-out for treatment
group z and drop-out probability p. Further, let rz,min (p), rz,med (p) and rz,max (p) denote
the elicited minimum, median, and maximum relative risks (see Table 1). Let pz,j (y j−1 ) =
(y)

P [Rj = 0|Rj−1 = 1, Y j−1 = y j−1 , Z = z] and let pz,j (y j−1 ) = P [Rj = 0|Rj−1 = 1, Y j−1 =
y j−1 , Yj = y, Z = z] for y = 0, 1.
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By definition,
(1)

(0)

rz (pz,j (y j−1 )) = pz,j (y j−1 )/pz,j (y j−1)
pz,j (y j−1 ) =

1
X

(y)

(y)

pz,j (y j−1 )πz,j (y j−1 )

y=0

(y)

where πz,j (y j−1 ) = P [Yj = y|Rj−1 = 1, Y j−1 = y j−1, Z = z] for y = 0, 1. This implies that
(0)

pz,j (y j−1 ) =

pz,j (y j−1 )
(1)
πz,j (y j−1 )(rz (pz,j (y j−1))

− 1) + 1

.

(0)

(1)

Since πz,j (y j−1 ) ∈ [0, 1], given pz,j (y j−1 ) and rz (pz,j (y j−1 )), pz,j (y j−1 ) is bounded as
follows:
for rz (pz,j (y j−1 )) ≥ 1,
(0)

pz,j (y j−1 )/rz (pz,j (y j−1 )) ≤ pz,j (y j−1 ) ≤ min{pz,j (y j−1 ), 1}
and, for rz (pz,j (y j−1)) ≤ 1,
(0)

pz,j (y j−1 ) ≤ pz,j (y j−1) ≤ min{pz,j (y j−1)/rz (pz,j (y j−1)), 1}.
We will use these bounds to construct our prior.
We construct the conditional prior of τz,j,y j−1 given pz,j (y j−1 ) using Steps 1-4 given
below. The general strategy is to use the elicited information on the relative risk at different
drop-out probabilities and the bounds derived above to construct the prior of interest.
Step 1. For m ∈ {min, med, max}, interpolate the elicited rz,m (p) at different drop-out probabilities (see Figure 1) to find rz,m (pz,j (y j−1 )) for any pz,j (y j−1).
Step 2. Construct the prior of rz (pz,j (y j−1 )) given pz,j (y j−1 ) as a 50-50 mixture of
Uniform(rz,min (pz,j (y j−1)), rz,med (pz,j (y j−1))
and
Uniform(rz,med(pz,j (y j−1)), rz,max (pz,j (y j−1 ))
random variables. This preserves the elicited percentiles of the relative risk.
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(0)

Step 3. Construct a conditional prior of pz,j (y j−1 ) given pz,j (y j−1 ) and rz (pz,j (y j−1 )) as a
uniform distribution with lower bound
pz,j (y j−1 )

max rz (pz,j (y j−1 )), 1

and upper bound
min

(

pz,j (y j−1 )
1


,
min rz (pz,j (y j−1 )), 1 max rz (pz,j (y j−1 )), 1

)

.

The bounds were derived above.

Step 4. Steps (2) and (3) induce a prior for τz,j,yj−1 |θ by noting
(0)

τz,j,yj−1 = log

rz (pz,j (y j−1 ))(1 − pz,j (y j−1 ))
(0)

1 − rz (pz,j (y j−1 ))pz,j (y j−1 )

!

,

(0)

i.e., τz,j,yj−1 is a deterministic function of rz (pz,j (y j−1 )) and pz,j (y j−1).
The relative risks elicited from Dr. Ganz are given in Table 2. We extrapolated the
relative risks outside the ranges given in Table 2 as shown in Figure 1.
Figure 2 shows the density of τ given pz,j (y j−1 ) equal 10% and 25% for the tamoxifen
and placebo arms. For two patients with the same response history up to time point j − 1,
the log odds ratio of dropping out at time point j, for the patient that is depressed at time
point j versus the patient that is not, increases as the overall drop out rate at time point j
increases. In general, for a given pz,j (y j−1 ), the log odds ratio is higher for patients in the
tamoxifen versus placebo arms.

6.3

Posterior Computation

With the shrinkage priors on θ, the elicited conditional priors τ given θ, and the observed
data, the following steps are used to simulate draws from the posterior of µ∗z,j :
1. Using the proposed observed data model with the shrinkage priors on θ, we simulate
draws from the posterior distributions of P [Yj = 1|Rj = 1, Y j−1 = y j−1 , Z = z] and
P [Rj = 0|Rj = 1, Y j−1 = y j−1 , Z = z] for all j, z and y j−1 in WinBUGS.
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2. For each draw of P [Rj = 0|Rj = 1, Y j−1 = y j−1 , Z = z], we draw τz,j,yj−1 based on
the conditional priors described in Section 6.2.
3. We compute µ∗z,j by plugging the draws of P [Yj = 1|Rj = 1, Y j−1 = y j−1 , Z = z],
P [Rj = 0|Rj = 1, Y j−1 = y j−1, Z = z] and τz,j,yj−1 into the identification algorithm
discussed in Section 4.
To sample from the posterior distributions of P [Yj = 1|Rj = 1, Y j−1 = y j−1, Z = z]
and P [Rj = 0|Rj = 1, Y j−1 = y j−1 , Z = z] in WinBUGS we stratify the individual binary
data (by previous response history) and analyze as Binomial data; this serves to drastically
improve the computational efficiency. Sampling τz,j,yj−1 and computing µ∗z,j is implemented
separately from the first step using R.

7

Assessment of Model Performance via Simulation

Via simulation, we compared the performance of the shrinkage model with a correct parametric model (given below), an incorrect parametric model (first order Markov model) and
the saturated model with diffuse priors (given below).
The shrinkage model uses the shrinkage priors proposed in Section 6.1 (shrink the saturated model toward a first order Markov model). Note that the shrinkage priors shrink the
saturated model to an incorrect parametric model.
For the saturated model with diffuse priors, we re-parameterize the model as
P [Yj = 1|Rj = 1, Y j−1 = y j−1, Z = z] = µz,y j−1
P [Rj = 0|Rj−1 = 1, Y j−1 = y j−1, Z = z] = ρz,,y j−1
for j = 1, . . . , 7, and specify independent Unif(0, 1) on µ’s and ρ’s.
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We simulated observed data from a ”true” parametric model of the following form:
logitP [Y0 = 1|R0 = 1, Z = z] = αz,0,0
logitP [Y1 = 1|R1 = 1, Y0 = y0 , Z = z] = αz,1,0 + αz,1,1y0
logitP [R1 = 0|R0 = 1, Y0 = y0 , Z = z] = γz,1,0 + γz,1,1y0
logitP [Yj = 1|Rj = 1, Y j−1 = y j−1 , Z = z] = αz,j,0 + αz,j,1yj−1 + αz,j,2yj−2
logitP [Rj = 0|Rj−1 = 1, Y j−1 = y j−1 , Z = z] = γz,j,0 + γz,j,1yj−1 + γz,j,2yj−2,
for j = 2 to 7.
We fit the ”true” model to the BCPT data and used the posterior mean of parameters
α and γ as the true parameters. We identify the full data model by using the elicited prior
from the BCPT (see Table 2). The parameters and the true depression rates µ∗z,j , computed
by Monte Carlo integration, are given in Table 3.
We considered (relatively) small (3000), moderate (5000), and large (10000) sample sizes
for each treatment arm; for each sample size, we simulated 50 datasets. We assessed model
performance using the mean squared error (MSE) criterion.
In Table 4, we report the MSEs of P [Yj = 1|Rj = 1, Y j−1 , Z = z] and P [Rj = 1|Rj−1 =
1, Y j−1, Z = z] averaged over all j and all Y j−1 (see columns 3 and 4, respectively). We also
report the MSEs for µ∗z,j (see columns 6-12). For reference, the MSEs associated with the true
data generating model are bolded. This table demonstrate that the shrinkage model generally
outperforms both the incorrectly specified parametric model and the saturated model at all
sample sizes. This improved performance is especially noticeable when comparing the MSEs
for the rates of depression at times 3-7.
In addition, the MSEs for the shrinkage model compare favorably with those of the true
parametric model for all sample sizes considered, despite the fact that the shrinkage priors
were specified to shrink toward an incorrect model.
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8

Application: Breast Cancer Prevention Trial (BCPT)

Table 5 displays the treatment-specific monotonized drop-out rates in the BCPT. By the 7th
study visit, more than 40% of patients had missed one or more assessments, with a slightly
higher percentage in the tamoxifen arm.
We fit the shrinkage model to the observed data using WinBUGS, with four chains of
8000 iterations and 1000 burn-in. Convergence was checked by examining trace plots of the
multiple chains.

8.1

Model Fit and Shrinkage Results

To assess the model fit, we compared the empirical rates and posterior means (with 95%
credible intervals) of P [Yj = 1, Rj = 1|Z = z] and P [Rj = 0|Z = z]. As shown in Figure 3,
the shrinkage model fits the observed data well. Figure 4 illustrates the effect of shrinkage on
the model fits by comparing the difference between the empirical rate and posterior mean of
P [Yj = 1|Rj = 1, Y j−1 , Z = z] for all j, z and Y j−1 . We can see that for early time points, the
difference is close to zero since there is little shrinkage applied to the model parameters. For
later time points, more higher order interaction coefficients are shrunk toward zero and the
magnitude of difference increases and drifts away from zero line. In general, the empirical
estimates are less reliable for the later time points (re: the simulation results in Section
7). In some cases, there are no observations within ”cells.” By shrinking the high order
interactions (i.e., borrowing information across neighboring cells), we are able to estimate
P [Yj = 1|Rj = 1, Y j−1 , Z = z] for all j, z and Y j−1 with reasonable precision.

8.2

Inference

Figure 5 shows the posterior of P [Y7 = 1|Z = z], the treatment-specific probability of
depression at the end of the 36-month follow up (solid lines). For comparison, the posterior
under MAR (corresponding to point mass priors for τ at zero) is also presented (dashed
http://biostats.bepress.com/jhubiostat/paper188
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lines). The observed depression rates (i.e., complete case analysis) were 0.115 on both
the placebo and tamoxifen arms. Under the MNAR analysis (using the elicited priors),
the posterior mean of the depression rates at month 36 were 0.126 (95%CI : 0.115, 0.138)
and 0.130 (95%CI : 0.119, 0.143) for the placebo and tamoxifen arms; the difference was
0.004 (95%CI : −0.012, 0.021). Under MAR, the rates were 0.125 (95%CI : 0.114, 0.136)
and 0.126 (95%CI : 0.115, 0.138) for the placebo and tamoxifen arms; the difference was
0.001 (95%CI : −0.015, 0.018). The posterior probability of depression was higher under the
MNAR analysis than the MAR analysis since researchers believed depressed patients were
more likely to drop out (see Table 2), a belief that was captured by the elicited priors. Figure
6 shows that under the two treatments there were no significant differences in the depression
rates at every time point (95% credible intervals all cover zero) under both MNAR and
MAR. Similar (non-significant) treatment differences were seen when examining treatment
comparisons conditional on depression status at baseline.

9

Summary and Discussion

In this paper, we have presented a Bayesian shrinkage approach for longitudinal binary
data with informative drop-out. Our model provides a framework that incorporates expert
opinion about non-identifiable parameters and avoids the curse of dimensionality by using
shrinkage priors. In our analysis of the BCPT data, we concluded that there was little (if
any) evidence that women on tamoxifen were more depressed than those on placebo.
An important feature of our approach is that the specification of models for the identifiable distribution of the observed data and the non-identifiable parameters can be implemented by separate independent data analysts. This feature can be used to increase the
objectivity of necessarily subjective inferences in the FDA review of randomized trials with
informative drop-out.
The ideas in this paper can be extended to continuous outcomes. For example, one could
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use the mixtures of Dirichlet processes model (Escobar and West, 1995) for the distribution of observed responses. They can also be extended to multiple cause dropout; in this
trial, missed assessments were due to a variety of reasons including patient-specific causes
such as experiencing a protocol defined event, stopping therapy, or withdrawing consent and
institution-specific causes such as understaffing an staff turnover. Therefore, some missingness is less likely to be informative; extensions will need to account for that. In addition,
institutional differences might be addressed by allowing institution-specific parameters with
priors that shrink them toward a common set of parameters.
For smaller sample sizes, WinBUGS has difficulty sampling from the posterior distribution of the parameters in the shrinkage model. Tailored sampling algorithms can be written
to overcome this difficulty. In addition, we are working on alternative parameterizations of
the saturated model for the observed data as well as alternative shrinkage prior specifications
to improve computational efficiency.
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Tables and Figures
Table 1: Relative Risks to be Elicited
Drop out Rate p
Question
Relative Risk p1 p2
...
100% confident the number is above
rz,min (p)
Best Guess
rz,med (p)
100% confident the number is below
rz,max (p)

Table 2: Percentiles of Relative Risks Elicited
Drop out Rate
Treatment Percentile 10%
25%
Tamoxifen Minimum 1.10
1.30
1.20
1.50
Median
1.60
Maximum 1.30
Placebo
Minimum 1.01
1.20
Median
1.05
1.30
Maximum 1.10
1.40
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Table 3: Simulation Scenario
Time Point
1
2
3
4

Parameter
0
Tamoxifen
α0
-2.578 -2.500 -2.613
α1
2.460 1.978
α2
1.500
γ0
-2.352 -2.871
γ1
0.611 0.397
γ2
0.121
Depression Rate 0.066 0.097 0.119
Placebo
α0
-2.653 -2.632 -2.59
α1
2.708 2.304
α2
1.241
γ0
-2.308 -2.970
γ1
0.466 0.468
γ2
-0.293
Depression Rate 0.071 0.107 0.118

5

6

7

-2.752 -2.626 -2.789 -2.811 -2.895
1.940 2.023 2.072 1.885 2.007
1.599 1.389 1.612 1.639 1.830
-2.625 -2.513 -2.281 -2.217 -2.536
0.460 0.247 0.320 0.127 0.228
0.422 0.261 0.035 0.293 0.204
0.124 0.139 0.126 0.126 0.123
-2.663 -2.598 -2.884 -2.853 -3.035
1.874 2.104 2.068 2.123 2.243
1.608 1.471 1.693 1.540 1.989
-2.729 -2.474 -2.410 -2.460 -2.673
0.469 0.272 0.376 0.088 0.001
0.323 0.278 0.288 0.241 0.428
0.120 0.132 0.130 0.126 0.125
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Table 4: Simulation Results: MSE (×103 ). P
respectively.
Observed
Model Treat
Y
R
1
Sample Size 3000
True
P
0.946 0.378 0.034
T
1.075 0.431 0.026
Parametric
P
30.176 0.451 0.034
T
28.882 0.385 0.026
Shrinkage
P
6.970 1.999 0.033
T
6.988 2.401 0.024
Saturated
P
35.678 67.171 0.036
T
34.654 62.606 0.026
Sample Size 5000
True
P
0.659 0.238 0.023
T
0.604 0.261 0.020
Parametric
P
30.029 0.381 0.023
T
28.571 0.277 0.020
Shrinkage
P
4.628 1.188 0.025
T
4.448 1.414 0.017
Saturated
P
30.274 54.647 0.023
T
29.599 51.219 0.020
Sample Size 10000
True
P
0.314 0.121 0.009
T
0.278 0.126 0.011
Parametric
P
29.849 0.315 0.009
T
28.418 0.223 0.011
Shrinkage
P
2.392 0.707 0.008
T
2.474 0.712 0.011
Saturated
P
22.989 37.716 0.009
T
22.245 34.791 0.011

Tamoxifen

Placebo

Table 5: Patients
Month
3
Available 5364
Drop out 490
Drop Rate(%) 9.13
Available 5375
Drop out 504
Drop Rate(%) 9.38

and T represent placebo and tamoxifen arms,

2

3

µ∗j,z
4

0.048
0.035
0.048
0.037
0.045
0.026
0.050
0.033

0.049
0.046
0.048
0.056
0.051
0.056
0.054
0.045

0.052
0.056
0.062
0.078
0.059
0.053
0.058
0.059

0.050
0.052
0.061
0.073
0.047
0.063
0.101
0.097

0.05
0.078
0.067
0.096
0.052
0.119
0.231
0.329

0.065
0.061
0.086
0.077
0.066
0.073
0.561
0.722

0.027
0.020
0.027
0.023
0.028
0.023
0.028
0.020

0.027
0.032
0.028
0.042
0.032
0.028
0.028
0.032

0.028
0.027
0.033
0.042
0.031
0.026
0.033
0.028

0.036
0.034
0.044
0.049
0.035
0.038
0.061
0.051

0.043
0.035
0.052
0.056
0.048
0.033
0.138
0.140

0.058
0.044
0.073
0.057
0.057
0.044
0.290
0.392

0.009
0.013
0.010
0.014
0.010
0.015
0.009
0.013

0.015
0.013
0.016
0.02
0.015
0.011
0.016
0.014

0.017
0.013
0.023
0.026
0.017
0.015
0.018
0.014

0.013
0.015
0.028
0.028
0.014
0.016
0.018
0.021

0.014
0.019
0.033
0.039
0.013
0.019
0.038
0.048

0.018
0.020
0.043
0.043
0.014
0.023
0.094
0.128

Cumulative Drop Out
6
12
18
4874 4597 4249
767
1115 1454
14.30 20.79 27.11
4871 4624 4310
751
1065 1424
13.97 19.81 26.49

5

6

7

Rate
24
30
36
3910 3529 3163
1835 2201 2447
34.21 41.03 45.62
3951 3593 3297
1782 2078 2304
33.15 38.66 42.87
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Figure 1: Extrapolation of the elicited relative risks.
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Figure 2: Prior conditional density τz,j,y j−1 given pz,j (y j−1 ). Black and gray lines represent
tamoxifen and placebo arms, respectively. Solid and dashed lines are for pz,j (y j−1 ) = 0.25
and pz,j (y j−1 ) = 0.10, respectively.
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Figure 3: Solid and dashed lines represent the empirical rate of P [Yj = 1, Rj = 1|Z = z] and
P [Rj = 0|Z = z], respectively. The posterior means of P [Yj = 1, Rj = 1|Z = z] (diamond)
and P [Rj = 0|Z = z] (triangle) and their 95% credible intervals are displayed at each time
point.
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C=6
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Pattern of Historical Response
Figure 4: Differences between posterior mean and empirical rate of P [Yj = 1|Rj =
1, Y j−1, Z = z] (A1 and A2) and P [Rj = 0|Rj−1 = 1, Y j−1 , Z = z] (B1 and B2). The
x-axis is ordered by follow up time C (max{t : Rt = 1}). The bullets are the posterior mean
of P [Yj = 1|Rj = 1, Y j−1, Z = z] and P [Rj = 0|Rj−1 = 1, Y j−1, Z = z] when there are no
patients with historical response Y j−1 .
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Figure 5: Posterior distribution of P [Y7 = 1|Z = z]. Black and gray lines represent tamoxifen
and placebo arms, respectively. Solid and dashed lines are for MNAR and MAR, respectively.
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Figure 6: Posterior mean and 95% credible interval of difference of P [Yj = 1|Z = z] between placebo and tamoxifen arms. The gray and white boxes are for MAR and MNAR,
respectively.
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